Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 7804.042 | 0.9460 | 0.9560 | 2.4955 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9024.018 | 1.0036 | 1.0026 | 2.8306 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9024.018 | 0.9942 | 0.9959 | 2.8306 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9024.018 | 0.9719 | 0.9799 | 2.8306 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9024.018 | 1.0773 | 1.0533 | 2.8306 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9024.018 | 0.9745 | 0.9818 | 2.8306 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9024.018 | 0.9177 | 0.9402 | 2.8306 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9024.018 | 0.9367 | 0.9543 | 2.8306 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 9024.018 | 0.8177 | 0.8627 | 2.8306 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 9024.018 | 0.8318 | 0.8740 | 2.8306 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 10261.026 | 1.0471 | 1.0374 | 2.4866 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 10261.026 | 1.0564 | 1.0446 | 2.4866 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 10261.026 | 1.0248 | 1.0198 | 2.4866 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 10261.026 | 1.0459 | 1.0364 | 2.4866 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 10261.026 | 1.0309 | 1.0246 | 2.4866 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 10261.026 | 0.9856 | 0.9884 | 2.4866 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 10261.026 | 1.0239 | 1.0191 | 2.4866 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 10261.026 | 1.0158 | 1.0126 | 2.4866 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 10261.026 | 0.9930 | 0.9943 | 2.4866 | |
| CAMA-1 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7805.018 | 1.0531 | 1.0924 | 1.1451 | |
| CAMA-1 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7805.018 | 0.9991 | 0.9984 | 1.1451 | |
| CAMA-1 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7805.018 | 1.0493 | 1.0858 | 1.1451 | |
| CAMA-1 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7805.018 | 1.0258 | 1.0450 | 1.1451 | |
| CAMA-1 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7805.018 | 1.0023 | 1.0041 | 1.1451 | |
| CAMA-1 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7805.018 | 1.0206 | 1.0360 | 1.1451 |